NeuroMetrix (NURO) Posts Smaller-than-Expected Q4 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
NeuroMetrix Reports Q4 and Full Year 2016 Financial Results
January 26, 2017 7:00 AM EST2016 revenue $12.0M up 65% year-on-year; Q4 revenue $3.7M up 36% Quell device shipments of 14.3K and electrode reorders of 20K represent new quarterly highs
WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO, NUROW), today reported financial and business highlights for the quarter and year ended December 31, 2016.
The Company develops and markets novel therapies, based on bioelectrical and digital medicine, for chronic conditions. The Companys primary product is Quell®, which is an over-the-counter wearable neurostimulation device for treating chronic pain that was launched in Q2... More
